A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects
- PMID: 11262198
- DOI: 10.1086/319680
A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects
Abstract
The major matrix phosphoprotein 65 (pp65) of cytomegalovirus (CMV) is an important target of HLA-restricted cytotoxic T cells (CTL) after natural infection. A canarypox-CMV pp65 recombinant was studied for its ability to induce CMV pp65-specific CTL, helper T lymphocytes, and antibodies in a phase I clinical trial. Twenty-one CMV-seronegative adult volunteers were randomized to receive immunizations at months 0, 1, 3, and 6 with either canarypox-CMV pp65 or placebo. In canarypox-CMV pp65-immunized subjects, pp65-specific CTL were elicited after only 2 vaccinations and were present at months 12 and 26 in all subjects tested. Cell-depletion studies indicated that the CTL were phenotype CD8(+). Peripheral blood mononuclear cells proliferated in response to stimulation with purified pp65, and antibodies specific for pp65 also were detected. Canarypox-CMV pp65 is the first recombinant vaccine to elicit CMV-specific CTL responses, which suggests the potential usefulness of this approach in preventing disease caused by CMV.
Similar articles
-
Rapid generation of CMV pp65-specific T cells for immunotherapy.J Immunother. 2007 Jul-Aug;30(5):557-61. doi: 10.1097/CJI.0b013e31803b945b. J Immunother. 2007. PMID: 17589296
-
Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.Biol Blood Marrow Transplant. 2001;7(5):247-56. doi: 10.1053/bbmt.2001.v7.pm11400946. Biol Blood Marrow Transplant. 2001. PMID: 11400946
-
Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.Hum Immunol. 2004 May;65(5):514-22. doi: 10.1016/j.humimm.2004.02.018. Hum Immunol. 2004. PMID: 15172452
-
The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.Vaccine. 2012 Nov 19;30(49):6980-90. doi: 10.1016/j.vaccine.2012.09.056. Epub 2012 Oct 3. Vaccine. 2012. PMID: 23041121 Review.
-
CD8(+) T-cell immunity to cytomegalovirus.Hum Immunol. 2004 May;65(5):456-64. doi: 10.1016/j.humimm.2004.02.014. Hum Immunol. 2004. PMID: 15172445 Review.
Cited by
-
A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.Expert Rev Vaccines. 2018 Oct;17(10):889-911. doi: 10.1080/14760584.2018.1526085. Epub 2018 Oct 3. Expert Rev Vaccines. 2018. PMID: 30246580 Free PMC article. Review.
-
Development of novel vaccines against human cytomegalovirus.Hum Vaccin Immunother. 2019;15(11):2673-2683. doi: 10.1080/21645515.2019.1593729. Epub 2019 Apr 24. Hum Vaccin Immunother. 2019. PMID: 31017831 Free PMC article. Review.
-
Can the triumph of mRNA vaccines against COVID-19 be extended to other viral infections of humans and domesticated animals?Microbes Infect. 2023 Jan-Feb;25(1-2):105078. doi: 10.1016/j.micinf.2022.105078. Epub 2022 Nov 23. Microbes Infect. 2023. PMID: 36435367 Free PMC article.
-
Stanley Plotkin: the bright spark of cytomegalovirus vaccines.Med Microbiol Immunol. 2015 Jun;204(3):243-5. doi: 10.1007/s00430-015-0392-3. Epub 2015 Mar 20. Med Microbiol Immunol. 2015. PMID: 25791891 Free PMC article. No abstract available.
-
Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.J Clin Virol. 2009 Dec;46 Suppl 4(Suppl 4):S73-6. doi: 10.1016/j.jcv.2009.07.002. Epub 2009 Jul 31. J Clin Virol. 2009. PMID: 19647480 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials